World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
53
Citations
10783
World Ranking
4082
National Ranking
1581

Jason M. Pogue publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Jason M. Pogue sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 225 publications — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Jason M. Pogue D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Jason M. Pogue sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 53 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Jason M. Pogue is affiliated with the University of Michigan-Ann Arbor in the United States. Their research spans primarily the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with notable contributions in subfields such as Molecular Medicine, Applied Microbiology and Biotechnology, Epidemiology, Pharmacology, and Infectious Diseases.

Their work focuses on several main topics, including:

  • Antibiotic Resistance in Bacteria
  • Antibiotic Use and Resistance
  • Antibiotics Pharmacokinetics and Efficacy
  • Bacterial Identification and Susceptibility Testing
  • Pneumonia and Respiratory Infections
  • Nosocomial Infections in ICU
  • COVID-19 Clinical Research Studies

Jason M. Pogue has authored research papers on a range of clinical and microbiological subjects. Recent publications include:

  • "Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19," 2020, Clinical Infectious Diseases
  • "Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial," 2020, The Lancet Infectious Diseases
  • "Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options," 2020, Open Forum Infectious Diseases
  • "Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms," 2020, Infectious Diseases and Therapy
  • "Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins," 2021, Clinical Microbiology and Infection

Frequent co-authors with whom Jason M. Pogue has collaborated include:

  • Keith S. Kaye
  • Walaiporn Wangchinda
  • Samuel L Aitken
  • Ryan K. Shields
  • Ellen G Kline

Jason M. Pogue's research has been disseminated through several publication venues, with the highest number of publications appearing in:

  • Open Forum Infectious Diseases
  • Clinical Infectious Diseases
  • Antimicrobial Agents and Chemotherapy
  • Infectious Diseases and Therapy
  • Clinical Microbiology and Infection

Best Publications

  • International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

    Brian T. Tsuji;Jason M. Pogue;Alexandre P. Zavascki;Mical Paul;Mical Paul

  • Tocilizumab for treatment of mechanically ventilated patients with COVID-19.

    Emily C Somers;Gregory A Eschenauer;Jonathan P Troost;Jonathan L Golob

  • Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections

    Haley J. Morrill;Jason M. Pogue;Keith S. Kaye;Kerry L. LaPlante

  • Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

    Richard G. Wunderink;Yuko Matsunaga;Mari Ariyasu;Philippe Clevenbergh

  • Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management

    Keith S. Kaye;Jason M. Pogue

  • Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system

    Jason M. Pogue;Jason M. Pogue;Jiha Lee;Dror Marchaim;Victoria Yee

  • Coronavirus disease 2019 treatment: A review of early and emerging options

    Erin K McCreary;Jason M Pogue

  • Outbreak of Colistin-Resistant, Carbapenem-Resistant Klebsiella pneumoniae in Metropolitan Detroit, Michigan

    Dror Marchaim;Teena Chopra;Jason M. Pogue;Federico Perez

  • A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.

    Natalie A. Finch;Evan J. Zasowski;Kyle P. Murray;Ryan P. Mynatt

  • Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.

    Bhagyashri Navalkele;Bhagyashri Navalkele;Jason M. Pogue;Shigehiko Karino;Shigehiko Karino;Bakht Nishan

  • Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa

    Jason M Pogue;Keith S Kaye;Michael P Veve;Twisha S Patel

  • Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations.

    Jason M Pogue;Jason M Pogue;Robert A Bonomo;Robert A Bonomo;Keith S Kaye

  • Agents of Last Resort: Polymyxin Resistance

    Keith S. Kaye;Jason M. Pogue;Thien B. Tran;Roger L. Nation

  • Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens

    J.M. Pogue;K.S. Kaye;D.A. Cohen;D. Marchaim

  • Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship.

    Dror Marchaim;Teena Chopra;Ashish Bhargava;Christopher Bogan

  • Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms.

    Janet Y. Wu;Pavithra Srinivas;Jason M. Pogue

  • Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management.

    Jason M Pogue;Tal Mann;Katie E Barber;Keith S Kaye

  • Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms.

    Unknown

  • Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin

    Evan J. Zasowski;Kyle P. Murray;Trang D. Trinh;Trang D. Trinh;Natalie A. Finch

  • Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli

    Teena Chopra;Dror Marchaim;Jennifer Veltman;Paul Johnson

  • Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae

    Joshua T. Thaden;Jason M. Pogue;Keith S. Kaye

  • Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines.

    Ravina Kullar;Steven N. Leonard;Susan L. Davis;Susan L. Davis;Susan L. Davis;George Delgado

  • Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy

    Anthony M. Casapao;Susan L. Davis;Susan L. Davis;Viktorija O. Barr;Kenneth P. Klinker

Frequent Co-Authors

Keith S. Kaye
Keith S. Kaye Rutgers, The State University of New Jersey
Michael J. Rybak
Michael J. Rybak Wayne State University
Emily T. Martin
Emily T. Martin University of Michigan–Ann Arbor
Robert A. Bonomo
Robert A. Bonomo Case Western Reserve University
Federico Perez
Federico Perez Case Western Reserve University
John S. Bradley
John S. Bradley University of California, San Diego
Sujata M. Bhavnani
Sujata M. Bhavnani University at Buffalo, State University of New York
Robert A. Bonomo
Robert A. Bonomo Case Western Reserve University
Roger L. Nation
Roger L. Nation Monash University
Michael N. Dudley
Michael N. Dudley Qpex Biopharma

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their expertise beyond microbiology, pursuing related online degrees can open up diverse career opportunities. For example, many students consider online public health masters programs easy to get into, which provide a strong foundation in community health, epidemiology, and health policy. These programs are ideal for microbiology graduates aiming to influence public health at a larger scale.

Another career pathway includes becoming a child life specialist, a role focused on supporting children through stressful medical experiences. If you are curious about the financial prospects in this field, resources outlining the child specialist salary can provide valuable insight into the profession’s benefits and challenges.

For those facing unique challenges, such as individuals with criminal records, pursuing higher education might seem daunting. However, there are options tailored to these circumstances. Explore degrees for felons that offer accessible and supportive pathways to career advancement.

Additionally, healthcare professionals with a microbiology background might consider advanced practice roles, such as a functional medicine nurse practitioner. Programs focused on functional medicine np programs integrate holistic and evidence-based approaches, appealing to those interested in innovative patient care models.

Best Scientists Citing Jason M. Pogue

Trending Scientists

Recently Published Articles